Author | David Spigel, MD | OncLive

Author | David Spigel, MD

Articles

Dr. Spigel Reflects on the PACIFIC Study in NSCLC

October 05, 2018

Video

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, reflects on the results of the PACIFIC trial in patients with non–small cell lung cancer.

Dr. Spigel on the Rationale Behind the PACIFIC Trial

March 08, 2018

Video

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the rationale behind the design of PACIFIC, a trial that investigated the use of durvalumab (Imfinzi) in patients with locally advanced, unresectable stage III lung cancer.

Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC

May 11, 2017

Video

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of pembrolizumab plus chemotherapy as a frontline treatment for patients with non–small cell lung cancer (NSCLC).

Dr. Spigel on Pembrolizumab/Chemo Combo in First-Line NSCLC

March 27, 2017

Video

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the results of cohort G from the KEYNOTE-021 trial, which explored pembrolizumab (Keytruda) combined with pemetrexed/carboplatin as a frontline treatment for patients with nonsquamous non–small cell lung cancer (NSCLC).

x